All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lymphoma & CLL content recommended for you
Denileukin diftitox-cxdl receives U.S. FDA approval for adult patients with R/R cutaneous T-cell lymphoma
On August 8, 2024, it was announced that the U.S. Food and Drug Administration (FDA) had granted approval to denileukin diftitox-cxdl, an IL-2-based immunotherapy, for the treatment of adult patients with relapsed/refractory (R/R) stage I–III cutaneous T-cell lymphoma (CTCL) after ≥1 prior systemic therapy. This approval was based on positive results from the phase III 302 trial (NCT01871727).1
The 302 trial1
The 302 trial is a multicenter, open-label, phase III study investigating the safety and efficacy of denileukin diftitox-cxdl in patients with R/R stage I–III CTCL. Among the evaluable patients with CTCL (n = 69):
- Overall response rate was 36.2%
- Complete response rate was 8.7%
- Durable and rapid responses were observed:
- Median time to response was 1.41 months
- Duration of response was ≥6 months for 52.0% of the patients
- 84.4% of skin evaluable patients had a decrease in skin tumor burden and 12.5% showed a complete clearing of skin disease
The most commonly reported adverse reactions in ≥20% of patients were laboratory abnormalities (increased transaminases, albumin decreased), nausea, edema, hemoglobin decreased, fatigue, musculoskeletal pain, rash, chills, constipation, pyrexia, and capillary leak syndrome.
Denileukin diftitox-cxdl comes with a boxed warning for capillary leak syndrome, including life-threatening or fatal reactions.
References
